This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY), the obesity and diabetes drugmaker, slipped about 0.3% to $1,181.45 at 10.15 EST time in Tuesday morning trading after it made a fresh case for its Foundayo pill against a higher dose of Novo Nordisk's oral semaglutide. The claim sounds strong. The comparison needs a closer look. Warning! GuruFocus has detected 7 Warning Sign with ABBV. Is LLY fairly valued? Test your thesis with our free DCF calculator.LLY GF Value chart In an analysis drawn from separate diabetes trials, Lilly said Foundayo's 17.2-milligram dose delivered 1.5% to 2.4% more weight loss and a 0.3% to 0.6% greater reduction in A1C than 25-milligram oral semaglutide, depending on the statistical method.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.